Oldest pages

From NeuroRehab.wiki

Showing below up to 50 results in range #1,351 to #1,400.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

  1. PITUITARY-LH & FSH‏‎ (11:07, 20 March 2023)
  2. OSTEOPOROSIS-DIAGNOSIS‏‎ (11:07, 20 March 2023)
  3. HYPOGLYCAEMIA-INVESTIGATION‏‎ (11:07, 20 March 2023)
  4. CALCIUM-METABOLISM‏‎ (11:07, 20 March 2023)
  5. LIPIDS-DOWN REGULATION OF LDL RECEPTORS‏‎ (11:07, 20 March 2023)
  6. DIABETES MELLITUS-SECONDARY PREVENTION OF CV DISEASES‏‎ (11:07, 20 March 2023)
  7. OSTEOPOROSIS-MANAGEMENT (ESTROGEN)‏‎ (11:07, 20 March 2023)
  8. DIABETES MELLITUS-ALPHA-GLUCOSIDASE INHIBITORS‏‎ (11:07, 20 March 2023)
  9. PITUITARY-ACTH‏‎ (11:07, 20 March 2023)
  10. HYPERTHYROIDISM-APATHETIC HYPERTHYROIDISM‏‎ (11:07, 20 March 2023)
  11. OSTEOPOROSIS-RISK FACTORS‏‎ (11:07, 20 March 2023)
  12. HYPOTHYROIDISM-PAINLESS THYROIDITIS‏‎ (11:07, 20 March 2023)
  13. PITUITARY-METASTASIS‏‎ (11:07, 20 March 2023)
  14. OSTEOPOROSIS-DISH‏‎ (11:07, 20 March 2023)
  15. HYPOGLYCEMIA‏‎ (11:07, 20 March 2023)
  16. LIPIDS-LIPOPROTEIN PATHWAYS‏‎ (11:07, 20 March 2023)
  17. DIABETES MELLITUS-SECRETAGOGUES‏‎ (11:07, 20 March 2023)
  18. HYPERPARATHYROIDISM-PRIMARY, INTRODUCTION‏‎ (11:07, 20 March 2023)
  19. OSTEOPOROSIS-MANAGEMENT (ESTROGEN SIDE EFFECTS)‏‎ (11:07, 20 March 2023)
  20. DIABETES MELLITUS-ANTIPLATELET THERAPY‏‎ (11:07, 20 March 2023)
  21. PITUITARY-ADH‏‎ (11:07, 20 March 2023)
  22. HYPERTHYROIDISM-CAUSES‏‎ (11:07, 20 March 2023)
  23. OSTEOPOROSIS-SCREENING‏‎ (11:07, 20 March 2023)
  24. HYPOTHYROIDISM-POSTPARTUM THYROIDITIS‏‎ (11:07, 20 March 2023)
  25. DIABETES MELLITUS-INVESTIGATION‏‎ (11:07, 20 March 2023)
  26. PHAEOCHROMOCYTOMA‏‎ (11:07, 20 March 2023)
  27. HYPOGLYCEMIA-NON REACTIVE HYPOGLYCEMIA‏‎ (11:07, 20 March 2023)
  28. LIPIDS-UP REGULATION OF LDL RECEPTORS‏‎ (11:07, 20 March 2023)
  29. DIABETES MELLITUS-SGLT 2 INHIBITORS‏‎ (11:07, 20 March 2023)
  30. HYPERPARATHYROIDISM-PRIMARY, INVESTIGATION‏‎ (11:07, 20 March 2023)
  31. OSTEOPOROSIS-MANAGEMENT (ROMOSOZUMAB)‏‎ (11:07, 20 March 2023)
  32. PITUITARY-ANTERIOR‏‎ (11:07, 20 March 2023)
  33. HYPERTHYROIDISM-CLINICAL FEATURES‏‎ (11:07, 20 March 2023)
  34. OSTEOPOROSIS-VITAMIN D‏‎ (11:07, 20 March 2023)
  35. HYPOTHYROIDISM-PRIMARY HYPOTHYROIDISM‏‎ (11:07, 20 March 2023)
  36. DIABETES MELLITUS-KETOACIDOSIS‏‎ (11:07, 20 March 2023)
  37. PHAEOCHROMOCYTOMA-COMPLICATIONS‏‎ (11:07, 20 March 2023)
  38. PITUITARY-PROLACTIN‏‎ (11:07, 20 March 2023)
  39. OSTEOPOROSIS-FRACTURE RISK CALCULATORS‏‎ (11:07, 20 March 2023)
  40. MYXEDEMA COMA‏‎ (11:07, 20 March 2023)
  41. DIABETES MELLITUS-SGLT 2 INHIBITOR INDICATIONS‏‎ (11:07, 20 March 2023)
  42. OSTEOPOROSIS-MANAGEMENT (SERM)‏‎ (11:07, 20 March 2023)
  43. DIABETES MELLITUS-COMPLICATIONS‏‎ (11:07, 20 March 2023)
  44. PITUITARY-APOPLEXY‏‎ (11:07, 20 March 2023)
  45. THYROID NODULE-RISK FACTORS‏‎ (11:07, 20 March 2023)
  46. HYPERTHYROIDISM-DIFFERENTIALS‏‎ (11:07, 20 March 2023)
  47. OSTEOPOROSIS-VITAMIN D SYNTHESIS‏‎ (11:07, 20 March 2023)
  48. CUSHING SYNDROME-CLINICAL‏‎ (11:07, 20 March 2023)
  49. LL LENGTH DISCREPANCY-TRUE‏‎ (11:07, 20 March 2023)
  50. REACTIVE ARTHRITIS‏‎ (11:07, 20 March 2023)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)